Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model‐informed precision dosing trial simulations

The recently released revised vancomycin consensus guideline endorsed area under the concentration‐time curve (AUC) guided monitoring. Means to AUC‐guided monitoring include pharmacokinetic (PK) equations and Bayesian software programs, with the latter approach being preferable. We aimed to evaluate...

Full description

Saved in:
Bibliographic Details
Published inClinical and translational science Vol. 15; no. 4; pp. 942 - 953
Main Authors Aljutayli, Abdullah, Thirion, Daniel J. G., Bonnefois, Guillaume, Nekka, Fahima
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.04.2022
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The recently released revised vancomycin consensus guideline endorsed area under the concentration‐time curve (AUC) guided monitoring. Means to AUC‐guided monitoring include pharmacokinetic (PK) equations and Bayesian software programs, with the latter approach being preferable. We aimed to evaluate the predictive performance of these two methods when monitoring using troughs or peaks and troughs at varying single or mixed dosing intervals (DIs), and evaluate the significance of satisfying underlying assumptions of steady‐state and model transferability. Methods included developing a vancomycin population PK model and conducting model‐informed precision dosing clinical trial simulations. A one‐compartment PK model with linear elimination, exponential between‐subject variability, and mixed (additive and proportional) residual error model resulted in the best model fit. Conducted simulations demonstrated that Bayesian‐guided AUC can, potentially, outperform that of equation‐based AUC predictions depending on the quality of model diagnostics and met assumptions. Ideally, Bayesian‐guided AUC predictive performance using a trough from the first DI was equivalent to that of PK equations using two measurements (peak and trough) from the fifth DI. Model transferability diagnostics can guide the selection of Bayesian priors but are not strong indicators of predictive performance. Mixed versus single fourth and/or fifth DI sampling seems indifferent. This study illustrated cases associated with the most reliable AUC predictions and showed that only proper Bayesian‐guided monitoring is always faster and more reliable than equations‐guided monitoring in pre‐steady‐state DIs in the absence of a loading dose. This supports rapid Bayesian monitoring using data as sparse and early as a trough at the first DI.
AbstractList The recently released revised vancomycin consensus guideline endorsed area under the concentration‐time curve (AUC) guided monitoring. Means to AUC‐guided monitoring include pharmacokinetic (PK) equations and Bayesian software programs, with the latter approach being preferable. We aimed to evaluate the predictive performance of these two methods when monitoring using troughs or peaks and troughs at varying single or mixed dosing intervals (DIs), and evaluate the significance of satisfying underlying assumptions of steady‐state and model transferability. Methods included developing a vancomycin population PK model and conducting model‐informed precision dosing clinical trial simulations. A one‐compartment PK model with linear elimination, exponential between‐subject variability, and mixed (additive and proportional) residual error model resulted in the best model fit. Conducted simulations demonstrated that Bayesian‐guided AUC can, potentially, outperform that of equation‐based AUC predictions depending on the quality of model diagnostics and met assumptions. Ideally, Bayesian‐guided AUC predictive performance using a trough from the first DI was equivalent to that of PK equations using two measurements (peak and trough) from the fifth DI. Model transferability diagnostics can guide the selection of Bayesian priors but are not strong indicators of predictive performance. Mixed versus single fourth and/or fifth DI sampling seems indifferent. This study illustrated cases associated with the most reliable AUC predictions and showed that only proper Bayesian‐guided monitoring is always faster and more reliable than equations‐guided monitoring in pre‐steady‐state DIs in the absence of a loading dose. This supports rapid Bayesian monitoring using data as sparse and early as a trough at the first DI.
Abstract The recently released revised vancomycin consensus guideline endorsed area under the concentration‐time curve (AUC) guided monitoring. Means to AUC‐guided monitoring include pharmacokinetic (PK) equations and Bayesian software programs, with the latter approach being preferable. We aimed to evaluate the predictive performance of these two methods when monitoring using troughs or peaks and troughs at varying single or mixed dosing intervals (DIs), and evaluate the significance of satisfying underlying assumptions of steady‐state and model transferability. Methods included developing a vancomycin population PK model and conducting model‐informed precision dosing clinical trial simulations. A one‐compartment PK model with linear elimination, exponential between‐subject variability, and mixed (additive and proportional) residual error model resulted in the best model fit. Conducted simulations demonstrated that Bayesian‐guided AUC can, potentially, outperform that of equation‐based AUC predictions depending on the quality of model diagnostics and met assumptions. Ideally, Bayesian‐guided AUC predictive performance using a trough from the first DI was equivalent to that of PK equations using two measurements (peak and trough) from the fifth DI. Model transferability diagnostics can guide the selection of Bayesian priors but are not strong indicators of predictive performance. Mixed versus single fourth and/or fifth DI sampling seems indifferent. This study illustrated cases associated with the most reliable AUC predictions and showed that only proper Bayesian‐guided monitoring is always faster and more reliable than equations‐guided monitoring in pre‐steady‐state DIs in the absence of a loading dose. This supports rapid Bayesian monitoring using data as sparse and early as a trough at the first DI.
The recently released revised vancomycin consensus guideline endorsed area under the concentration-time curve (AUC) guided monitoring. Means to AUC-guided monitoring include pharmacokinetic (PK) equations and Bayesian software programs, with the latter approach being preferable. We aimed to evaluate the predictive performance of these two methods when monitoring using troughs or peaks and troughs at varying single or mixed dosing intervals (DIs), and evaluate the significance of satisfying underlying assumptions of steady-state and model transferability. Methods included developing a vancomycin population PK model and conducting model-informed precision dosing clinical trial simulations. A one-compartment PK model with linear elimination, exponential between-subject variability, and mixed (additive and proportional) residual error model resulted in the best model fit. Conducted simulations demonstrated that Bayesian-guided AUC can, potentially, outperform that of equation-based AUC predictions depending on the quality of model diagnostics and met assumptions. Ideally, Bayesian-guided AUC predictive performance using a trough from the first DI was equivalent to that of PK equations using two measurements (peak and trough) from the fifth DI. Model transferability diagnostics can guide the selection of Bayesian priors but are not strong indicators of predictive performance. Mixed versus single fourth and/or fifth DI sampling seems indifferent. This study illustrated cases associated with the most reliable AUC predictions and showed that only proper Bayesian-guided monitoring is always faster and more reliable than equations-guided monitoring in pre-steady-state DIs in the absence of a loading dose. This supports rapid Bayesian monitoring using data as sparse and early as a trough at the first DI.The recently released revised vancomycin consensus guideline endorsed area under the concentration-time curve (AUC) guided monitoring. Means to AUC-guided monitoring include pharmacokinetic (PK) equations and Bayesian software programs, with the latter approach being preferable. We aimed to evaluate the predictive performance of these two methods when monitoring using troughs or peaks and troughs at varying single or mixed dosing intervals (DIs), and evaluate the significance of satisfying underlying assumptions of steady-state and model transferability. Methods included developing a vancomycin population PK model and conducting model-informed precision dosing clinical trial simulations. A one-compartment PK model with linear elimination, exponential between-subject variability, and mixed (additive and proportional) residual error model resulted in the best model fit. Conducted simulations demonstrated that Bayesian-guided AUC can, potentially, outperform that of equation-based AUC predictions depending on the quality of model diagnostics and met assumptions. Ideally, Bayesian-guided AUC predictive performance using a trough from the first DI was equivalent to that of PK equations using two measurements (peak and trough) from the fifth DI. Model transferability diagnostics can guide the selection of Bayesian priors but are not strong indicators of predictive performance. Mixed versus single fourth and/or fifth DI sampling seems indifferent. This study illustrated cases associated with the most reliable AUC predictions and showed that only proper Bayesian-guided monitoring is always faster and more reliable than equations-guided monitoring in pre-steady-state DIs in the absence of a loading dose. This supports rapid Bayesian monitoring using data as sparse and early as a trough at the first DI.
Author Nekka, Fahima
Thirion, Daniel J. G.
Aljutayli, Abdullah
Bonnefois, Guillaume
AuthorAffiliation 4 Certara Inc. Montréal Quebec Canada
2 Department of Pharmaceutics Faculty of Pharmacy Qassim University Buraydah Saudi Arabia
5 Laboratoire de Pharmacométrie Faculté de Pharmacie Université de Montréal Montréal Quebec Canada
3 Department of Pharmacy McGill University Health Center Montréal Quebec Canada
6 Centre de recherches mathématiques Université de Montréal Montréal Quebec Canada
1 Faculty of Pharmacy Université de Montréal Montréal Quebec Canada
AuthorAffiliation_xml – name: 6 Centre de recherches mathématiques Université de Montréal Montréal Quebec Canada
– name: 2 Department of Pharmaceutics Faculty of Pharmacy Qassim University Buraydah Saudi Arabia
– name: 3 Department of Pharmacy McGill University Health Center Montréal Quebec Canada
– name: 5 Laboratoire de Pharmacométrie Faculté de Pharmacie Université de Montréal Montréal Quebec Canada
– name: 1 Faculty of Pharmacy Université de Montréal Montréal Quebec Canada
– name: 4 Certara Inc. Montréal Quebec Canada
Author_xml – sequence: 1
  givenname: Abdullah
  surname: Aljutayli
  fullname: Aljutayli, Abdullah
  email: abdullah.aljutayli@umontreal.ca
  organization: Qassim University
– sequence: 2
  givenname: Daniel J. G.
  surname: Thirion
  fullname: Thirion, Daniel J. G.
  organization: McGill University Health Center
– sequence: 3
  givenname: Guillaume
  surname: Bonnefois
  fullname: Bonnefois, Guillaume
  organization: Certara Inc
– sequence: 4
  givenname: Fahima
  surname: Nekka
  fullname: Nekka, Fahima
  organization: Université de Montréal
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35170243$$D View this record in MEDLINE/PubMed
BookMark eNp9ksuKFDEUhoOMOBdd-AIScKOLnklSlbq4GNDGy8CAguM6nKRO9aStSnqSqpbe-QhufEGfxEzX2DgNGgg5JP_5Tv7kHJMD5x0S8pSzU57GmRniKc8EZw_IES-lmFWsEAe7WOaH5DjGJWNFVlTyETnMJC-ZyLMj8vPTNYQejP9qHQ7WULwZYbDeRbrGEMdI38AGowVHF6NtsKFrcMb3G2Md7b2zgw_WLV7RfU7vG-wouGaKfn3_YV3rQ58Iq4DGxlSDNj6mZDoECx2Nth-7qfZj8rCFLuKTu_WEfHn39mr-YXb58f3F_PXlzMhSslldVg3mMhlpAXWd522lW9GKnENd56wxdVYJIQ0XyDVwCXUjqowbiXmZZpudkIuJ23hYqlWwPYSN8mDVdsOHhYKQ3HSo6lLrQleQXq7OK85AMJZi1Bqh0sIk1vnEWo06uTTohgDdPej9E2ev1cKvVc04E1IkwIs7QPA3I8ZB9TYa7Dpw6MeoRCGSn0oWt9Lne9KlH4NLT5VUkrGaF0wm1bO_b7S7yp_fT4KXk8AEH2PAdifhTN12lkqdpbadlbRne1pjh-1vJTO2-1_GN9vh5t9oNb_6PGX8Bm6R4_o
CitedBy_id crossref_primary_10_1111_bcp_16334
crossref_primary_10_1128_aac_00699_24
crossref_primary_10_1002_prp2_1026
crossref_primary_10_1097_FTD_0000000000001226
crossref_primary_10_3343_alm_2024_0218
crossref_primary_10_1002_phar_2722
crossref_primary_10_1016_j_biopha_2022_113777
crossref_primary_10_1002_phar_4623
crossref_primary_10_1002_psp4_13253
crossref_primary_10_1111_cts_13626
crossref_primary_10_3390_antibiotics12020301
crossref_primary_10_1007_s40262_023_01233_7
crossref_primary_10_1007_s13318_024_00897_1
crossref_primary_10_1093_jac_dkae374
crossref_primary_10_3390_antibiotics12091441
crossref_primary_10_3389_fphar_2023_1252757
Cites_doi 10.5414/CP203033
10.1093/ajhp/zxaa036
10.1111/jcpt.12995
10.1002/psp4.12422
10.1007/s10928-020-09695-z
10.1016/j.cmpb.2005.04.005
10.1002/cpt.2065
10.1111/j.1365-2710.2008.01016.x
10.1007/s40262-020-00866-2
10.1093/ajhp/zxz070
10.1002/phar.1531
10.1128/AAC.02042-17
10.1016/j.cmi.2019.02.029
10.1002/9781118784860
10.1007/s13318-018-0534-2
10.1007/s40262-018-0727-5
10.1002/cpdd.638
10.1038/psp.2013.24
10.1890/03-0757
10.1002/psp4.12353
10.3389/fphar.2020.00620
10.1146/annurev-pharmtox-033020-113257
10.1111/j.1365-2125.2005.02547.x
10.1016/j.addr.2014.05.016
10.1111/bcp.14360
10.1007/978-0-387-98141-3
10.1007/978-1-4419-9485-1
10.1086/491712
10.1093/cid/ciaa1354
10.1002/phar.2191
10.2165/11596390-000000000-00000
ContentType Journal Article
Copyright 2022 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2022 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
– notice: 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
– notice: 2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7T5
7TK
7TM
7U9
7X7
7XB
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M7N
M7P
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
7X8
5PM
DOA
DOI 10.1111/cts.13210
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection (UHCL Subscription)
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef

Publicly Available Content Database

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Bayesian vs. Equation Vancomycin Monitoring
EISSN 1752-8062
EndPage 953
ExternalDocumentID oai_doaj_org_article_97bb6b8a51794810a200517ebbea8b2c
PMC9010252
35170243
10_1111_cts_13210
CTS13210
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Pfizer
– fundername: NSERC Industrial Research Chair in Pharmacometrics
– fundername: NSERC Discovery
  funderid: RGPIN‐2020‐05982
– fundername: ;
– fundername: NSERC Discovery
  grantid: RGPIN‐2020‐05982
GroupedDBID ---
05W
0R~
10A
1OC
24P
29B
31~
4.4
52S
53G
5GY
5VS
7X7
8-1
8FE
8FH
8FI
8FJ
AAHHS
AANHP
AAZKR
ABDBF
ABUWG
ACBWZ
ACCFJ
ACCMX
ACRPL
ACUHS
ACXQS
ACYXJ
ADKYN
ADNMO
ADZMN
ADZOD
AEEZP
AEQDE
AFBPY
AFKRA
AFZJQ
AIWBW
AJBDE
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AVUZU
BBNVY
BDRZF
BENPR
BHPHI
BPHCQ
BRXPI
BVXVI
CAG
CCPQU
COF
CS3
DIK
EBD
EBS
EJD
EMOBN
ESX
F5P
FEDTE
FYUFA
G-S
GODZA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
IAO
IHR
ITC
KQ8
LH4
LK8
LW6
M7P
MY~
O9-
OIG
OK1
P2P
PIMPY
PQQKQ
PROAC
QB0
ROL
RPM
SUPJJ
SV3
TUS
UKHRP
WIN
XG1
AAYXX
AGQPQ
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PQGLB
3V.
7QP
7T5
7TK
7TM
7U9
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
H94
K9.
M7N
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c5750-978de45243faeb944f8bf2f241a9940dc938225c12e1ba15a9d2831c5e475e4f3
IEDL.DBID 24P
ISSN 1752-8054
1752-8062
IngestDate Wed Aug 27 01:14:40 EDT 2025
Thu Aug 21 14:09:36 EDT 2025
Tue Aug 05 10:53:29 EDT 2025
Wed Aug 13 04:30:47 EDT 2025
Mon Jul 21 05:46:01 EDT 2025
Tue Jul 01 01:05:37 EDT 2025
Thu Apr 24 23:06:37 EDT 2025
Wed Jan 22 16:24:38 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License Attribution-NonCommercial
2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5750-978de45243faeb944f8bf2f241a9940dc938225c12e1ba15a9d2831c5e475e4f3
Notes Funding information
This work was supported by the NSERC Industrial Research Chair in Pharmacometrics, jointly supported by Syneos Health and Pfizer, and NSERC Discovery Grant RGPIN‐2020‐05982, held by F. Nekka. Abdullah Aljutayli is a recipient of a Qassim University scholarship.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcts.13210
PMID 35170243
PQID 2650091605
PQPubID 2029979
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_97bb6b8a51794810a200517ebbea8b2c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9010252
proquest_miscellaneous_2629388562
proquest_journals_2650091605
pubmed_primary_35170243
crossref_primary_10_1111_cts_13210
crossref_citationtrail_10_1111_cts_13210
wiley_primary_10_1111_cts_13210_CTS13210
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2022
PublicationDateYYYYMMDD 2022-04-01
PublicationDate_xml – month: 04
  year: 2022
  text: April 2022
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Clinical and translational science
PublicationTitleAlternate Clin Transl Sci
PublicationYear 2022
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2019; 8
2015; 35
2021; 109
2021; 6
2013; 2
2020; 86
2011
2020; 61
2019; 76
1997; 276
2019; 58
2009
2020; 59
2018; 62
2020; 77
2020; 11
2021; 72
2012; 51
2018; 7
2009; 34
2006; 42
2006; 61
2020; 75
2021
2019; 44
2019; 25
2018
2020; 47
2014
2018; 56
2018; 38
2014; 77
2005; 79
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
e_1_2_8_25_1
e_1_2_8_26_1
e_1_2_8_27_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_22_1
e_1_2_8_23_1
Beal S (e_1_2_8_31_1) 2018
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_19_1
Bradley N (e_1_2_8_13_1) 2021
e_1_2_8_36_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_15_1
e_1_2_8_16_1
Hughes DM (e_1_2_8_9_1) 2020; 75
Stewart JJ (e_1_2_8_5_1) 2021; 6
e_1_2_8_32_1
e_1_2_8_10_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
References_xml – volume: 62
  start-page: e02042‐1
  issue: 2
  year: 2018
  end-page: 17
  article-title: Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing
  publication-title: Antimicrob Agents Chemother
– year: 2011
– year: 2009
– volume: 276
  start-page: 122
  year: 1997
  end-page: 126
  article-title: A general model for the origin of allometric scaling laws in biology
  publication-title: Science
– volume: 58
  start-page: 767
  year: 2019
  end-page: 780
  article-title: Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations
  publication-title: Clin Pharmacokinet
– volume: 56
  start-page: 56
  year: 2018
  article-title: Investigation of the age dependency of vancomycin clearance by population pharmacokinetic modeling
  publication-title: Int J Clin Pharmacol Ther
– volume: 7
  start-page: 785
  year: 2018
  end-page: 787
  article-title: Model‐informed precision dosing at the bedside: scientific challenges and opportunities
  publication-title: CPT Pharmacomet Syst Pharmacol
– volume: 47
  start-page: 431
  issue: 5
  year: 2020
  end-page: 446
  article-title: Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine
  publication-title: Journal of Pharmacokinetics and Pharmacodynamics
– volume: 77
  start-page: 835
  year: 2020
  end-page: 864
  article-title: Therapeutic monitoring of vancomycin for serious methicillin‐resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
  publication-title: Am J Health Syst Pharm
– volume: 44
  start-page: 361
  year: 2019
  end-page: 370
  article-title: Development of a population pharmacokinetic model of vancomycin and its application in Chinese geriatric patients with pulmonary infections
  publication-title: Eur J Drug Metab Pharmacokinet
– volume: 11
  start-page: 620
  year: 2020
  article-title: Software tools for model‐informed precision dosing: how well do they satisfy the needs?
  publication-title: Frontiers Pharmacol
– volume: 59
  start-page: 671
  issue: 6
  year: 2020
  end-page: 698
  article-title: An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults
  publication-title: Clinical Pharmacokinetics
– volume: 38
  start-page: 1174
  year: 2018
  end-page: 1183
  article-title: Review and validation of Bayesian dose‐optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients
  publication-title: Pharmacotherapy
– volume: 2
  start-page: 1
  issue: 6
  year: 2013
  end-page: 9
  article-title: Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose
  publication-title: CPT: Pharmacometrics & Systems Pharmacology
– year: 2018
– volume: 25
  start-page: 1286.e1
  year: 2019
  end-page: 1286.e7
  article-title: Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting
  publication-title: Clin Microbiol Infect
– year: 2014
– volume: 35
  start-page: 127
  year: 2015
  end-page: 139
  article-title: Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections
  publication-title: Pharmacotherapy
– volume: 6
  start-page: 3
  issue: 1
  year: 2021
  end-page: 9
  article-title: A Canadian perspective on the revised 2020 ASHP–IDSA–PIDS–SIDP guidelines for vancomycin AUC‐based therapeutic drug monitoring for serious MRSA infections
  publication-title: Official J Assoc Med Microbiol Infect Dis Can
– volume: 72
  start-page: e675
  issue: 10
  year: 2021
  end-page: e681
  article-title: Vancomycin Advanced Therapeutic Drug Monitoring: Exercise in Futility or Virtuous Endeavor to Improve Drug Efficacy and Safety?
  publication-title: Clinical Infectious Diseases
– volume: 75
  start-page: 434
  year: 2020
  end-page: 437
  article-title: Bayesian clinical decision support‐guided versus clinician‐guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population
  publication-title: J Antimicrob Chemother
– volume: 79
  start-page: 241
  year: 2005
  end-page: 257
  article-title: PsN‐Toolkit—a collection of computer intensive statistical methods for non‐linear mixed effect modeling using NONMEM
  publication-title: Comput Methods Programs Biomed
– volume: 8
  start-page: 538
  year: 2019
  end-page: 556
  article-title: NONMEM tutorial part II: estimation methods and advanced examples
  publication-title: CPT Pharmacomet Syst Pharmacol
– volume: 44
  start-page: 750
  year: 2019
  end-page: 759
  article-title: A new population pharmacokinetic model for vancomycin in patients with variable renal function: therapeutic drug monitoring based on extended covariate model using CKD‐EPI estimation
  publication-title: J Clin Pharm Ther
– volume: 51
  start-page: 1
  year: 2012
  end-page: 13
  article-title: Vancomycin
  publication-title: Clin Pharmacokinet
– volume: 61
  start-page: 225
  issue: 1
  year: 2020
  end-page: 245
  article-title: Model‐informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy
  publication-title: Annu Rev Pharmacol Toxicol
– volume: 61
  start-page: 164
  year: 2006
  end-page: 176
  article-title: Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery
  publication-title: Br J Clin Pharmacol
– start-page: 1
  year: 2021
  end-page: 6
  article-title: Assessment of the Implementation of AUC Dosing and Monitoring Practices With Vancomycin at Hospitals Across the United States
  publication-title: Journal of Pharmacy Practice
– volume: 34
  start-page: 473
  year: 2009
  end-page: 483
  article-title: Population pharmacokinetic analysis of vancomycin in patients with gram‐positive infections and the influence of infectious disease type
  publication-title: J Clin Pharm Ther
– volume: 42
  start-page: S35
  year: 2006
  end-page: S39
  article-title: The pharmacokinetic and pharmacodynamic properties of vancomycin
  publication-title: Clin Infect Dis
– volume: 8
  start-page: 418
  year: 2019
  end-page: 425
  article-title: Toward dynamic prescribing information: codevelopment of companion model‐informed precision dosing tools in drug development
  publication-title: Clin Pharmacol Drug Dev
– volume: 77
  start-page: 50
  year: 2014
  end-page: 57
  article-title: Innovative approaches to optimizing the delivery of vancomycin in individual patients
  publication-title: Adv Drug Deliv Rev
– volume: 109
  start-page: 175
  issue: 1
  year: 2021
  end-page: 183
  article-title: A Model averaging/selection approach improves the predictive performance of model‐informed precision dosing: vancomycin as a case study
  publication-title: Clin Pharm Ther
– volume: 86
  start-page: 2497
  issue: 12
  year: 2020
  end-page: 2506
  article-title: Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients
  publication-title: Br J Clin Pharmacol
– volume: 76
  start-page: 889
  year: 2019
  end-page: 894
  article-title: Readiness to implement vancomycin monitoring based on area under the concentration–time curve: a cross‐sectional survey of a national health consortium
  publication-title: Am J Health‐System Pharm
– ident: e_1_2_8_26_1
  doi: 10.5414/CP203033
– ident: e_1_2_8_2_1
  doi: 10.1093/ajhp/zxaa036
– ident: e_1_2_8_29_1
  doi: 10.1111/jcpt.12995
– ident: e_1_2_8_20_1
  doi: 10.1002/psp4.12422
– ident: e_1_2_8_21_1
  doi: 10.1007/s10928-020-09695-z
– ident: e_1_2_8_15_1
  doi: 10.1016/j.cmpb.2005.04.005
– ident: e_1_2_8_6_1
  doi: 10.1002/cpt.2065
– ident: e_1_2_8_28_1
  doi: 10.1111/j.1365-2710.2008.01016.x
– ident: e_1_2_8_23_1
  doi: 10.1007/s40262-020-00866-2
– ident: e_1_2_8_12_1
  doi: 10.1093/ajhp/zxz070
– ident: e_1_2_8_25_1
  doi: 10.1002/phar.1531
– ident: e_1_2_8_4_1
  doi: 10.1128/AAC.02042-17
– volume: 75
  start-page: 434
  year: 2020
  ident: e_1_2_8_9_1
  article-title: Bayesian clinical decision support‐guided versus clinician‐guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population
  publication-title: J Antimicrob Chemother
– ident: e_1_2_8_36_1
  doi: 10.1016/j.cmi.2019.02.029
– ident: e_1_2_8_19_1
  doi: 10.1002/9781118784860
– ident: e_1_2_8_27_1
  doi: 10.1007/s13318-018-0534-2
– volume-title: NONMEM 7.4. 3 Users Guides (1989‐2018)
  year: 2018
  ident: e_1_2_8_31_1
– ident: e_1_2_8_24_1
  doi: 10.1007/s40262-018-0727-5
– start-page: 1
  year: 2021
  ident: e_1_2_8_13_1
  article-title: Assessment of the Implementation of AUC Dosing and Monitoring Practices With Vancomycin at Hospitals Across the United States
  publication-title: Journal of Pharmacy Practice
– ident: e_1_2_8_8_1
  doi: 10.1002/cpdd.638
– ident: e_1_2_8_17_1
  doi: 10.1038/psp.2013.24
– ident: e_1_2_8_16_1
  doi: 10.1890/03-0757
– ident: e_1_2_8_22_1
  doi: 10.1002/psp4.12353
– ident: e_1_2_8_35_1
  doi: 10.3389/fphar.2020.00620
– ident: e_1_2_8_7_1
  doi: 10.1146/annurev-pharmtox-033020-113257
– ident: e_1_2_8_30_1
  doi: 10.1111/j.1365-2125.2005.02547.x
– ident: e_1_2_8_32_1
  doi: 10.1016/j.addr.2014.05.016
– ident: e_1_2_8_34_1
  doi: 10.1111/bcp.14360
– volume: 6
  start-page: 3
  issue: 1
  year: 2021
  ident: e_1_2_8_5_1
  article-title: A Canadian perspective on the revised 2020 ASHP–IDSA–PIDS–SIDP guidelines for vancomycin AUC‐based therapeutic drug monitoring for serious MRSA infections
  publication-title: Official J Assoc Med Microbiol Infect Dis Can
– ident: e_1_2_8_18_1
  doi: 10.1007/978-0-387-98141-3
– ident: e_1_2_8_10_1
  doi: 10.1007/978-1-4419-9485-1
– ident: e_1_2_8_3_1
  doi: 10.1086/491712
– ident: e_1_2_8_14_1
  doi: 10.1093/cid/ciaa1354
– ident: e_1_2_8_11_1
  doi: 10.1002/phar.2191
– ident: e_1_2_8_33_1
  doi: 10.2165/11596390-000000000-00000
SSID ssj0063685
Score 2.356509
Snippet The recently released revised vancomycin consensus guideline endorsed area under the concentration‐time curve (AUC) guided monitoring. Means to AUC‐guided...
The recently released revised vancomycin consensus guideline endorsed area under the concentration-time curve (AUC) guided monitoring. Means to AUC-guided...
Abstract The recently released revised vancomycin consensus guideline endorsed area under the concentration‐time curve (AUC) guided monitoring. Means to...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 942
SubjectTerms Accuracy
Anti-Bacterial Agents
Antibiotics
Area Under Curve
Bayes Theorem
Bayesian analysis
Clinical trials
Creatinine
Dosage
Drug Monitoring - methods
Drug therapy
Humans
Pharmacokinetics
Population
Simulation
Software
Staphylococcus infections
Vancomycin
Vancomycin - pharmacokinetics
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELaqHlAvCGiBQEGm4tBLYO3YScyNVq0qpFaVaKXeIv_Cqmy2NLuH3ngELrwgT8KM7V11oYgLh0j5mThOPBN_tme-IeR1oznzrnZlCHVdCq55qVtpSwT_wVVKSIkBzscn9dG5-HAhL26l-kKfsEQPnD7cW9UYU5tWI5WUaNlI80gr5Y3xujXc4t8X-rzFYCr9g2ukVY-hkBLsHVBJ5hRCHx47G94wjFxZ6YkiYf9dKPNPZ8nbIDb2QocPyP0MH-n7VO2HZM33j8i947xAvkl-nGYq6ks4BBnqvyYu74Gi_8V8oHv6xmPgJP00HzvvKLoATCc3cDudRPvGib539PdyYsYcqnuX9n5--54oV6GEq-ucp4e6Kc480JgJhA7jSU4NNmyR88ODs_2jMmdeKC3At1EJQ0vnheSiCtobJURoTeABenutlBg5qyoAFtIy7pnRTGrlAKYwK71oYAvVY7LeT3v_lFDFg2JGSleNgrCsNpW2jQi8aWVd8ZYVZHfRCp3NtOSYHeNLtxieQIN1scEKsrMUvUpcHHcJ7WFTLgWQPjueAKXqslJ1_1KqgmwvFKHLNj10HMAsaBqM_wryankZrBGXWHTvp3OUAfjUwqvxgjxJerOsSQVPQP7HgjQrGrVS1dUr_fhzZPxGHxouoczdqHt_f_tu_-xj3Hn2Pz7Dc7LBMdojOiptk_XZ9dy_AAw2My-juf0CWqoyGQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgLojxTCjKIQy-BtWPn0UtFK6oKqQiJVtpb5Ge7gk22m91Db_0JXPiD_BJmHG_KQuGwUjaZOLFmJv5sz3xDyJtCceZsblPv8zwVXPFUldKkCP69zSohJSY4H3_Kj07Fx7EcxwW3LoZVrr6J4UNtW4Nr5O84QAkY2wB9780uUqwahbursYTGbXIHqcvQqovxMOHKkVw9JERK8HrAJpFZCCN5zKJ7yzB_ZW08CrT9N2HNv0Mmf4eyYSw6fEDuRxBJ3_da3yS3XPOQ3D2O2-SPyI_PkZD6K_wFGeouekbvjmIUxrKj--rSYfokPVtOrLMUAwHa6SXcTqfBy3G5b5f-2U6om0NVY_ujn1ffe-JVaGE2j9V6qG1x_YGGeiC0m0xjgbDuMTk9_HBycJTG-gupARA3SmGCaZ2QXGReOV0J4UvtuYcxX1WVGFlTZQAvpGHcMa2YVJUFsMKMdKKAn8-ekI2mbdwzQivuK6altNnIC8NynSlTCM-LUuYZL1lCdlZaqE0kJ8caGd_q1SQFFFYHhSXk9SA66xk5bhLaR1UOAkiiHU6087M6-mRdFVrnulTIUiZKNlI8MJY5rZ0qNTcJ2V4ZQh09u6uv7TAhr4bL4JO40aIa1y5RBkBUCV3jCXna283wJhk8AVkgE1KsWdTaq65faSbngfcbI2m4hDZ3gu39u_f1wcmXcLD1_x48J_c4ZnOEQKRtsrGYL90LwFgL_TI40i8eXimN
  priority: 102
  providerName: ProQuest
Title Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model‐informed precision dosing trial simulations
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcts.13210
https://www.ncbi.nlm.nih.gov/pubmed/35170243
https://www.proquest.com/docview/2650091605
https://www.proquest.com/docview/2629388562
https://pubmed.ncbi.nlm.nih.gov/PMC9010252
https://doaj.org/article/97bb6b8a51794810a200517ebbea8b2c
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF6VVkJcKt4YSrQgDr0YxetdP-BEqlYVUqsIWik3a58lgthtnBx64ydw4Q_yS5hZr60GisQhkR2PN7ZmP--365lvCHmTS5ZYk5nYuSyLOZMsloXQMZJ_Z9KSC4EJzien2fE5_zgTsy3yvs-F6fQhhgU3RIZ_XiPApWpvgFyv2rcJZqDcITuYWovxfIxP-8dwhsrqPhtSAOSBmARZIQzjGU7dGIy8Zv9tRPPveMmbPNYPREf3yW5gkPRD5_IHZMvWD8ndk_CO_BH5OQ1q1F9hF2yoverkvFuKIRjrlk7ktcXcSXqxnhtrKEYBNItrOJ0uPMRxre8d_bMdXzSHytp0W7--_-hUV6GFy2Uo1UNNg4sP1BcDoe18EaqDtY_J-dHh2cFxHIovxBoY3DiG2aWxXDCeOmlVybkrlGMOBnxZlnxsdJkCtxA6YTZRMhGyNMBUEi0sz-Hj0idku25q-4zQkrkyUUKYdOy4TjKVSp1zx_JCZCkrkojs916odFAmxwIZ36p-hgIOq7zDIvJ6ML3s5DhuM5qgKwcDVND2PzTLiyoAsipzpTJVSJQo40UylszLlVmlrCwU0xHZ6ztCFWDdVgz4LBAsmAJG5NVwGACJb1lkbZs12gCDKuDWWESedv1muJIU_gElICOSb_SojUvdPFLPv3jRbwyjYQLa3Pd97993Xx2cffYbz__f9AW5xzCtw0ck7ZHt1XJtXwLZWqmRBxV857N8RHYmh6fTTyO_cPEbdXUtHA
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIgEXxBtDgQWB1IuLvd71AwkhWqhS2lRIpFJuZl8uEcRO40QoN34CF_4GP4pfwszaDgQKtx4iOfZ47dWM57E78w0hjxPJQmti4xdFHPucSebLVGgfnf_CRBkXAguc-4dx74i_GYrhGvne1cJgWmWnE52iNpXGNfKnDFwJsG3gfb-YnPjYNQp3V7sWGo1Y7NvFZwjZ6ud7r4C_TxjbfT3Y6fltVwFfg2sS-BA2GcsF41Ehrco4L1JVsAIsmcwyHhidRWA0hQ6ZDZUMhcwMmOBQC8sT-BURjHuOnAfDG2CwlwyXAV6MYO6uAFOAlgFfqEUywswhPau3QqyXWbF_rk3Aab7t3ymav7vOzvbtXiGXW6eVvmyk7CpZs-U1cqHfbstfJ9_etgDYH-Ev0FB70iCI1xSzPuY13ZYLi-Wa9Hg-MtZQTDyoxgu4nY6dVsHlxWf0z3Fcnx4qS9Mc_fjytQF6hREm07Y7EDUVrndQ13-E1qNx25CsvkGOzoQzN8l6WZX2NqEZK7JQCWGioOA6jFUkdcILlqQijlgaemSz40KuWzB07MnxKe-CImBY7hjmkUdL0kmDAHIa0TayckmAoN3uRDU9zlsdkGeJUrFKJaKi8TQMJHMIaVYpK1PFtEc2OkHIW01S57_k3iMPl5dBB-DGjixtNUcacNpSmBrzyK1GbpZvEsETEHXSI8mKRK286uqVcvTB4Yxj5g4TMOamk71_zz7fGbxzB3f-P4MH5GJv0D_ID_YO9--SSwwrSVwS1AZZn03n9h74dzN1331UlLw_66_4J_ZyZWI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJ028IP4TGGAQSHsJaxw7f5AQotuqjbFqgk3aW7Bje1TQpGtaob7xEXjhy_Bx-CTcOUmhMHjbQ6W0cZ1Yd7772b77HSFPYskCoyPtWxtFPmeS-TIRuY_g3-ow5UJggvPBINo95q9PxMkK-d7mwmBYZWsTnaHWZY575JsMoAT4NkDfm7YJizjc7r8cn_lYQQpPWttyGrWK7Jv5Z1i-VS_2tkHWTxnr7xxt7fpNhQE_B5jS9WEJpQ0XjIdWGpVybhNlmQWvJtOUd3WehuBARR4wEygZCJlqcMdBLgyP4WND6PcSWY1xVdQhq72dweHb1g9ESO3u0jEF2BxARg2vEcYR5dPqWYDZM0ve0BUNOA_p_h2w-TuQdp6wf5VcaSAsfVXr3DWyYorrZO2gOaS_Qb4dNnTYH-ErtKHmrOYTryjGgMwq2pNzg8mb9HQ21EZTDEMoR3P4Ox05G4Objc_pn_24qj1UFrq--vHla037Cj2MJ02tIKpL3P2grhoJrYajpjxZdZMcX4hsbpFOURbmDqEps2mghNBh1_I8iFQo85hbFiciClkSeGSjlUKWN9ToWKHjU9YukUBgmROYRx4vmo5rPpDzGvVQlIsGSOHtfignp1ljEbI0VipSiUSONJ4EXckcX5pRyshEsdwj660iZI1dqbJfs8Ajjxa3wSLgMY8sTDnDNgDhEhga88jtWm8WbxLCE5CD0iPxkkYtverynWL4wbGOYxwPE9DnhtO9f48-2zp65y7u_n8ED8kazODszd5g_x65zDCtxEVErZPOdDIz9wHsTdWDZlZR8v6iJ_JPj1Nq_Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetic+equations+versus+Bayesian+guided+vancomycin+monitoring%3A+Pharmacokinetic+model+and+model%E2%80%90informed+precision+dosing+trial+simulations&rft.jtitle=Clinical+and+translational+science&rft.au=Aljutayli%2C+Abdullah&rft.au=Thirion%2C+Daniel+J.+G.&rft.au=Bonnefois%2C+Guillaume&rft.au=Nekka%2C+Fahima&rft.date=2022-04-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=1752-8054&rft.eissn=1752-8062&rft.volume=15&rft.issue=4&rft.spage=942&rft.epage=953&rft_id=info:doi/10.1111%2Fcts.13210&rft_id=info%3Apmid%2F35170243&rft.externalDocID=PMC9010252
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1752-8054&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1752-8054&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1752-8054&client=summon